Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $26.4 million.

  • BridgeBio Pharma's Change in Accured Expenses rose 139609.29% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.6 million, marking a year-over-year increase of 133337.07%. This contributed to the annual value of $17.0 million for FY2024, which is 11771.34% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Change in Accured Expenses is $26.4 million, which was up 139609.29% from $46.0 million recorded in Q2 2025.
  • BridgeBio Pharma's Change in Accured Expenses' 5-year high stood at $46.0 million during Q2 2025, with a 5-year trough of -$19.4 million in Q1 2025.
  • For the 5-year period, BridgeBio Pharma's Change in Accured Expenses averaged around $4.4 million, with its median value being $4.5 million (2021).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 9308.81% in 2022, then soared by 236964.29% in 2023.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Change in Accured Expenses stood at $18.6 million in 2021, then tumbled by 92.51% to $1.4 million in 2022, then soared by 758.44% to $12.0 million in 2023, then soared by 97.34% to $23.6 million in 2024, then grew by 11.96% to $26.4 million in 2025.
  • Its Change in Accured Expenses stands at $26.4 million for Q3 2025, versus $46.0 million for Q2 2025 and -$19.4 million for Q1 2025.